Yeleswaram Krishnaswamy 4
4 · Rapport Therapeutics, Inc. · Filed Apr 21, 2026
Research Summary
AI-generated summary of this filing
Rapport Therapeutics CDO Y. Krishnaswamy Sells 20,225 Shares
What Happened
Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics (RAPP), sold 20,225 shares on April 17, 2026. The reported weighted-average sale price was $39.99 per share, for total proceeds of approximately $808,844. This was a sale (code S) — sales are often routine dispositions rather than a direct bullish signal.
Key Details
- Transaction date: 2026-04-17 (reported on Form 4 filed 2026-04-21).
- Price: weighted average $39.99; individual trade prices ranged from $39.90 to $40.38 (footnote).
- Total shares sold: 20,225; total proceeds ≈ $808,844.
- Post-transaction holdings: Not disclosed in the supplied excerpt of the filing.
- Footnotes:
- F1 — Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted December 10, 2025 (prearranged plan).
- F2 — The price is a weighted average; the filer will provide a per-price breakdown on request.
- Timeliness: Filed 2026-04-21 for a 2026-04-17 trade. Form 4s are typically due within two business days of a transaction, so this filing appears outside that usual window.
Context
Because the sale was executed under a Rule 10b5-1 plan, it was prearranged and may reflect planned liquidity rather than contemporaneous insider views on the company. For retail investors, purchases generally carry more informational weight than routine sales; this filing documents proceeded disposition of holdings totaling about $0.8M.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-04-17$39.99/sh−20,225$808,844→ 246,426 total
Footnotes (2)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.